Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,110.00 at Royal Bank of Canada

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) had its target price boosted by investment analysts at Royal Bank of Canada from $1,076.00 to $1,110.00 in a report released on Monday, Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price suggests a potential upside of 18.36% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Deutsche Bank Aktiengesellschaft started coverage on Regeneron Pharmaceuticals in a research report on Thursday, November 9th. They issued a “hold” rating and a $800.00 target price on the stock. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 5th. Piper Sandler increased their target price on Regeneron Pharmaceuticals from $885.00 to $895.00 and gave the stock an “overweight” rating in a report on Friday, November 3rd. Finally, Truist Financial restated a “buy” rating and issued a $1,045.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, December 18th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $939.05.

Read Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $937.81 on Monday. The firm has a market cap of $102.17 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 2.86 and a beta of 0.11. Regeneron Pharmaceuticals has a 1-year low of $684.80 and a 1-year high of $973.99. The firm’s fifty day moving average price is $892.41 and its 200 day moving average price is $837.71. The company has a debt-to-equity ratio of 0.10, a current ratio of 6.41 and a quick ratio of 5.74.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the firm earned $10.96 EPS. The business’s revenue for the quarter was up .6% compared to the same quarter last year. On average, sell-side analysts expect that Regeneron Pharmaceuticals will post 39.36 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $817.30, for a total value of $81,730.00. Following the completion of the sale, the director now owns 18,447 shares of the company’s stock, valued at $15,076,733.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $817.30, for a total transaction of $81,730.00. Following the completion of the transaction, the director now owns 18,447 shares of the company’s stock, valued at approximately $15,076,733.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph L. Goldstein sold 2,707 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the transaction, the director now directly owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. Insiders sold 10,911 shares of company stock valued at $9,831,770 over the last quarter. Insiders own 8.83% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Sunbelt Securities Inc. bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $25,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth about $26,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $31,000. MCF Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares in the last quarter. Finally, Criterion Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $37,000. 84.15% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.